



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07K 14/00</p>	A2	<p>(11) International Publication Number: WO 99/51629</p> <p>(43) International Publication Date: 14 October 1999 (14.10.99)</p>		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(21) International Application Number: PCT/EP99/02361</p> <p>(22) International Filing Date: 7 April 1999 (07.04.99)</p> <p>(30) Priority Data: 98106302.7 7 April 1998 (07.04.98) EP 98124837.0 30 December 1998 (30.12.98) EP</p> <p>(71) Applicant (for all designated States except US): ROCHE DIAGNOSTICS GMBH [DE/DE]; D-68298 Mannheim (DE).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): KITAS, Eric, Argirios [AU/CH]; In der Schappe 5, CH-4144 Arlesheim (CH). SCHLAEGER, Ernst-Jürgen [DE/DE]; Neue Strasse 63, D-79588 Effringen-Kirchen (DE).</p> <p>(74) Common Representative: ROCHE DIAGNOSTICS GMBH; Patent Dept., D-68298 Mannheim (DE).</p> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p> </td> </tr> </table>			<p>(21) International Application Number: PCT/EP99/02361</p> <p>(22) International Filing Date: 7 April 1999 (07.04.99)</p> <p>(30) Priority Data: 98106302.7 7 April 1998 (07.04.98) EP 98124837.0 30 December 1998 (30.12.98) EP</p> <p>(71) Applicant (for all designated States except US): ROCHE DIAGNOSTICS GMBH [DE/DE]; D-68298 Mannheim (DE).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): KITAS, Eric, Argirios [AU/CH]; In der Schappe 5, CH-4144 Arlesheim (CH). SCHLAEGER, Ernst-Jürgen [DE/DE]; Neue Strasse 63, D-79588 Effringen-Kirchen (DE).</p> <p>(74) Common Representative: ROCHE DIAGNOSTICS GMBH; Patent Dept., D-68298 Mannheim (DE).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(21) International Application Number: PCT/EP99/02361</p> <p>(22) International Filing Date: 7 April 1999 (07.04.99)</p> <p>(30) Priority Data: 98106302.7 7 April 1998 (07.04.98) EP 98124837.0 30 December 1998 (30.12.98) EP</p> <p>(71) Applicant (for all designated States except US): ROCHE DIAGNOSTICS GMBH [DE/DE]; D-68298 Mannheim (DE).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): KITAS, Eric, Argirios [AU/CH]; In der Schappe 5, CH-4144 Arlesheim (CH). SCHLAEGER, Ernst-Jürgen [DE/DE]; Neue Strasse 63, D-79588 Effringen-Kirchen (DE).</p> <p>(74) Common Representative: ROCHE DIAGNOSTICS GMBH; Patent Dept., D-68298 Mannheim (DE).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>			
<p>(54) Title: NEW COMPOUNDS FOR DNA-TRANSFECTION</p> <div style="text-align: center; margin: 20px 0;"> $\begin{array}{c} \text{CH}_2\text{---OR}^1 \\ \\ \text{CH}_2\text{---OR}^2\text{---OH} \\ \\ \text{CH}_2\text{---O---P(=O)(OH)---O---CH}_2\text{---CH}_2\text{---NHCO---Y---X---R}^3 \end{array} \quad (I)$ </div> <p>(57) Abstract</p> <p>The invention relates to conjugates of lipids and basic, modified membrane disturbing peptides, characterized in that the peptides comprises a reversed amide backbone, particularly compounds of formula (I), wherein R¹ and R² are a hydrocarbyl moiety of a straight-chain or branched-chain, saturated or unsaturated aliphatic carboxylic acid or a phospholipid moiety, R³ is a basic, modified membrane disturbing peptide with a reversed amide backbone, Y is C₂₋₁₀ alkylene, X is -C(O)-NH- or -S-S-, and salts thereof.</p>				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

NEW COMPOUNDS FOR DNA-TRANSFECTION

The present invention is concerned with novel compounds especially useful for non-viral introduction of biologically active molecules such as DNA, RNA, peptides or proteins into eukaryotic cells.

Non-viral systems have been developed to carry DNA into cells, e.g., the transfection technique based on a cationic lipid, the dioleoyloxypropyl trimethylammonium (Felgner et al., Proc. Natl., Acad. Sci. USA, 1987, 84, 7413-7417) commercialized as Lipofectin™. Since the discovery of this transfection technique, many more cationic lipids have been synthesized and some are commercially available as transfecting reagent for laboratory use: DOGS (Transfectam™), DOSPA (Lipofectamine™), DOTAP (DOTAP™).

Transfection of cells with oligonucleotides such as DNA can be used, for example to express in a host cell or organism, a protein which is not normally expressed by that cell or organism. For example, a DNA molecule called a plasmid may be introduced into a cell that does not normally contain the gene (s) encoded by that plasmid in order to express a marker gene product in that cell, or to express a protein of interest such as a recombinant protein which is later harvested from such cells (See Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd ed. (Cold Spring Harbor, 1989), ch. 1.). The transfection of oligonucleotides into cells can also be used therapeutically. For example, antisense oligonucleotides, once in the cell or cell nucleus, bind to target single-stranded nucleic acid molecules by Watson-Crick base pairing or to double stranded nucleic acids by Hoogsteen base pairing, and in doing so disrupt the function of the target by one of several mechanisms: by preventing the binding of factors required for normal transcription, splicing, or translation; by triggering the enzymatic degradation of mRNA by RNase H, or by destroying the target via reactive groups attached directly to the antisense oligonucleotide. (See Zamecnik et al., Proc. Natl. Acad. Sci.-USA, 1978, 75, 280-284). Gene therapy or DNA based vaccination are other therapeutic applications.

Proteins and other macromolecules are transfected into cells for therapeutic and screening purposes. For example, immunization is enhanced by introducing an immunogenic protein into a cell, so that it is more efficiently processed and presented on the surface of the cells, thereby enhancing the immunogenic response. Negatively charged macromolecules which act

inside a cell are transported past the cell membrane into the cytoplasm where they exert their effect. Factors which enhance or hinder transcription of DNA can be used in a screening test to verify the transcription of a gene of interest. These transcription assays are very well known for use in screening compounds to determine their effect against a particular macromolecule, for example a cell receptor.

Cell-lytic antibacterial peptides that act by perturbing the barrier function of membranes are reviewed in Saberwal, et al., *Biochim. Biophys. Acta*, 1994, 1197, 109-131. Certain fatty acid-bearing basic peptides having antibacterial activity are disclosed in Vogler, et al., *Helv. Chim. Acta*, 1964, 47, 526-543. Poly(lysine-serine) random polymers for use as carriers to transport oligonucleotides into cells is disclosed in European Patent Publication No. EP-A-727 223.

European Patent Publication No. EP-A-784 984 and Legendre et al. (*Bioconjugate Chem.*, 1997, 8, 57-63) describe conjugates of a lipid and a basic, membrane disturbing peptide that bind polynucleotides and anionic macromolecules can be used for transfection of cells. The peptide portion of the conjugate consists of natural amino acids linked by a natural amide binding.

Nevertheless, despite important progress in the formulation of non-viral gene delivery systems, there remains a need for more efficient techniques, since the transfection efficiency of synthetic systems is usually below that of viral vectors. Furthermore, still many problems arise in vivo and in vitro due in part to the poor stability of the non-viral systems in biological fluids and culture media does not allow high and reproducible levels of transfection.

Many known compounds used for transfection experiments are toxic for eukaryotic cells. In addition problems may occur in scaling up where the conditioned medium reduces the effect of known transfecting agents.

The present invention is directed to novel compounds which avoid disadvantages associated with known transfection agents.

In one aspect, the invention is concerned with novel compounds which are conjugates of lipids and a modified basic membrane disturbing peptide, characterized in that the peptides comprise a reversed amide backbone.

The term "conjugates" means compounds consisting of a lipid chemically bound to the peptide, e.g., via a disulfide bond formed between a sulfur atom present in or attached to the lipid

and a sulfur atom present in or attached to the peptide; or an amide bond formed between the carboxyl group present in or attached to the lipid and an amino group of the peptide.

The term "lipid" as used herein comprises straight-chain, branched-chain, saturated or unsaturated aliphatic carboxylic acids and phospholipids. Examples of aliphatic carboxylic acids are lauric acid, palmitic acid, stearic acid, oleic acid and $(\text{CH}_3(\text{CH}_2)_n)_2\text{CH COOH}$, where n is an integer from 3 to 19. Examples of phospholipids are phosphatidylethanolamines such as dioleoylphosphatidylethanolamine.

The term "basic peptides" denotes peptides containing at least one basic amino acid.

Examples of such basic amino acids are natural and unnatural diamino-monocarboxylic acids, such as alpha-, beta-diaminopropionic acid, alpha-, gamma-diaminobutyric acid, lysine, arginine, ornithine and p-aminophenylalanine, etc.

The term "membrane disturbing peptides" denotes cell-lytic or antibacterial peptides that perturb the barrier function of membranes (G. Saberwal and R. Nagaraj, BBA, 1994, 1197, 109-131). Examples of basic, cell-lytic peptides are melittin, hemolysin, mastoparan, bombolitin, crabrolin and derivatives thereof. Examples of basic antibacterial peptides are cecropins, magainins, gramicidin S and tyrocidine and derivatives thereof.

The term "derivatives" refers to peptides wherein one or more amino acid residues are missing, have been added or have been replaced by another amino acid residue without substantially changing the biological activity of the original peptide concerned, i.e. allow transfection of a macromolecule, preferably a polynucleotide, into a cell. The term "derivatives" also refers to peptides wherein the terminal carboxyl group is esterified, particularly to form lower alkyl esters such as the methyl and ethyl ester; or converted into an amide, lower alkyl amide or di-lower alkyl amide or hydrazide. The term "derivatives" also relates to peptides wherein the NH_2 -group of the N-terminus may be acylated to form an amide or a lower alkyl amide. In particular, the NH_2 -group is acetylated. The term "lower" denotes groups containing from 1-6 carbon atoms.


The term "reversed amide backbone" refers to retro-peptides which characteristically have the same composition as its parent peptide, but the sequence is reversed, i.e., $n, \dots 3, 2, 1$ instead of $1, 2, 3, \dots n$ when reading both in the N to C direction. Both have normal peptide bonds.

Throughout this application the following standard abbreviations are used to refer to amino acids:

Alanine	Ala	A
Glutamate	Glu	E
Glutamine	Gln	Q
Aspartate	Asp	D
Asparagine	Asn	N
Leucine	Leu	L
Glycine	Gly	G
Lysine	Lys	K
Serine	Ser	S
Valine	Val	V
Arginine	Arg	R
Threonine	Thr	T
Proline	Pro	P
Isoleucine	Ile	I
Methionine	Met	M
Phenylalanine	Phe	F
Tyrosine	Tyr	Y
Cysteine	Cys	C
Tryptophan	Trp	W
Histidine	His	H
Ornithine	Orn	O
D-Alanine	D-Ala	a
D-Glutamate	D-Glu	e
D-Glutamine	D-Gln	q
D-Aspartate	D-Asp	d
D-Asparagine	D-Asn	n
D-Leucine	D-Leu	l
D-Lysine	D-Lys	k
D-Serine	D-Ser	s
D-Valine	D-Val	v
D-Arginine	D-Arg	r
D-Threonine	D-Thr	t
D-Proline	D-Pro	p

D-Isoleucine	D-Ile	i
D-Methionine	D-Met	m
D-Phenylalanine	D-Phe	f
D-Tyrosine	D-Tyr	y
D-Cysteine	D-Cys	c
D-Tryptophan	D-Trp	w
D-Histidine	D-His	h
D-Ornithine	D-Orn	o

In a preferred embodiment, the novel compounds of the present invention are compounds of formula



wherein R^1 and R^2 are a hydrocarbyl moiety of a straight-chain or branched-chain, saturated or unsaturated aliphatic carboxylic acid or a phospholipid moiety, R^3 is a basic, membrane-disturbing peptide with a reversed amide backbone, Y is C_{2-10} alkylene, X is $-C(O)-NH-$ or $-S-S-$, and salts thereof.

Particularly preferred compounds are those wherein R^1 and R^2 independently are an acyl moiety of a C_{12-20} carboxylic acid. The term " C_{12-20} " denotes a number of carbon atoms of from 12 to 20. The acyl moieties R^1 and R^2 can be a straight-chain or branched-chain, saturated or unsaturated moiety. Examples of such moieties are lauroyl, palmitoyl, stearoyl and oleoyl. In a preferred aspect, R^1 and R^2 are oleoyl. Y is preferably ethylene, propylene or decamethylene. X is preferably $-S-S-$.


R^3 is a basic, membrane disturbing peptide with a reversed amide backbone. For example, R^3 is Gln-Gln-Arg-Lys-Arg-Lys-Ile-Trp-Ser-Ile-Leu-Ala-Pro-Leu-Gly-Thr-Thr-Leu-Val-Lys-Leu-Val-Ala-Gly-Ile-NH-CH[CONH₂](CH₂)-. The peptide has a reversed amide backbone. Preferably, R^3 comprises at least 50%, more preferably 65%, and even more preferably 80% of D-amino acids or derivatives thereof. In the most preferred embodiment all amino acids are D-amino acids. The term "D-amino acid" refers to naturally as well as non-naturally D- α -amino carbonic acids or derivatives thereof. In addition R^3 also comprises membrane-disturbing peptide sequences such as magainin, cecropin, defensins, etc., or chimers of such e.g.,

cecropin-melittin (Hancock & Lehrer TIBTECH, 1998, vol. 16, 82-88) synthesized as the retro-inverso peptides and derivatized to allow conjugation to lipids, analogous to the methods as described below, especially analogous in fashion to Example 1.

The term "retro-inverso peptide" is the all -D analogue of an all -L retro peptide.

In a further preferred embodiment, R^3 is D-Gln-D-Gln-D-Arg-D-Lys-D-Arg-D-Lys-D-Ile-D-Trp-D-Ser-D-Ile-D-Leu-D-Ala-D-Pro-D-Leu-Gly-D-Thr-D-Thr-D-Leu-D-Val-D-Lys-D-Leu-D-Val-D-Ala-Gly-D-Ile-NH-[CONH₂]-CH-(CH₂)-

The most preferred compound is




A further embodiment of the present invention refers to the peptide portion of R^3 , especially to the intermediate peptide Gln-Gln-Arg-Lys-Arg-Lys-Ile-Trp-Ser-Ile-Leu-Ala-Pro-Leu-Gly-Thr-Thr-Leu-Val-Lys-Leu-Val-Ala-Gly-Ile-Cys-NH₂ or derivatives and/or salts and/or solvates thereof having a reversed amide backbone and consisting of at least 50%, more preferably 65%, and even more preferably 80% of D-amino acids or derivatives thereof. In the most preferred embodiment all amino acids are D-amino acids. The term "D-amino acid" refers to naturally as well as non-naturally D- α -amino carbonic acids or derivatives thereof.

In a preferred embodiment the peptide is D-Gln-D-Gln-D-Arg-D-Lys-D-Arg-D-Lys-D-Ile-D-Trp-D-Ser-D-Ile-D-Leu-D-Ala-D-Pro-D-Leu-Gly-D-Thr-D-Thr-D-Leu-D-Val-D-Lys-D-Leu-D-Val-D-Ala-Gly-D-Ile-D-Cys-NH₂.


In another aspect, this invention relates to a process for preparing the novel compounds defined above, i.e., conjugates of lipids and basic, membrane disturbing peptides wherein the peptides comprise a reversed amide backbone, and compositions comprising at least one such compound, a polynucleotide or any other anionic macromolecule, and, optionally, a helper lipid and/or a short chain phospholipid, and/or a cationic lipid and optionally an additional known transfection reagent other than a conjugate of this invention (i.e. a compound of formula I or II). In still another aspect, this invention relates to compositions comprising conjugates of lipids and basic, membrane disturbing peptides and a helper lipid and/or a short

chain phospholipid, and/or a cationic lipid or and optionally an additional known transfection reagent other than a conjugate of this invention, e.g. a compound of formula I. The invention further relates to the use of the novel compounds as a carrier for transfecting a cell with a polynucleotide or any other anionic macromolecule.

The compounds provided by this invention can be prepared by reacting a peptide of the formula R^3NH_2 with a lipid of the formula



or a peptide of the formula R^3SH with a lipid of the formula



wherein R^1 , R^2 , R^3 and Y are as defined above and Z is a leaving group such as 2-pyridinethio. These reactions can be carried out in a manner known per se.


Compounds of the formula R^3NH_2 wherein the peptide part is comprises a reversed amide backbone may be prepared by methods known in the art. The corresponding methods have been described for example for the preparation of synthetic melittin, its enantio, retro, and retroenantio isomers and derivatives thereof (Juvvadi et al. (1996) J. Am. Chem. Soc. 118, 8989-8997).

The peptides may be prepared by the solid-phase synthesis technique. In this technique, synthesis is occurring while the peptide is attached to a polymeric support, therefore allowing for the separation of product from byproduct by washing steps. The completion of the acylation reaction is ensured by using large excesses of soluble reagents. Synthesis involves the covalent anchorage of the first amino acid in the sequence to the solid support followed by the deprotection of the protected amino function for the subsequent coupling to the incoming amino acid derivative. After n cycles of deprotection and coupling, the peptide is released from the solid phase by a chemical cleavage reaction. In a preferred embodiment, D-amino acids are used.


Thus, the coupling of peptide of the formula R^3NH_2 with a lipid of the formula II can be accomplished by reacting the compounds wherein amino group other than the amino group to be reacted are protected in a suitable solvent in the presence of a condensation agent such as dicyclohexylcarbodiimide in analogy to methods known for producing peptide bonds.

The reaction of a peptide of the formula R^3SH with a compound of formula R-SZ can be carried out in an appropriate solvent or solvent mixture which solubilizes both reactants. The compound of formula R-SZ can be dissolved in an organic solvent, e.g., in chloroform. The peptide R^3SH is suitably dissolved in aqueous buffer solution, such as phosphate buffer, that contains an appropriate amount of a water-miscible organic solvent such as acetonitrile to accomplish the formation of a single phase reaction system.

Compounds of the formula II and III are known or can be prepared by known methods, e.g. as described in Biochim. Biophys. Acta, 1986 862, 435-439. For example, compounds of the formula



wherein R^1 and R^2 are oleoyl, and Y is ethylene, propylene or decamethylene and the compound of the formula



wherein R^1 and R^2 are oleoyl, Y is ethylene and Z is 2-pyridinethio are commercially available as N-Succinyl-PE, N-Glutaryl-PE, N-Dodecanyl-PE and N-PDP-PE from Avanti Polar Lipids, Alabaster, Alabama, USA.

Any anionic macromolecule can be transfected into a cell using a compound of formula I. An anionic macromolecule is a macromolecule which contains at least one negative charge per molecule. Examples of anionic macromolecules which can be transfected in accordance with this invention include polynucleotides, such as deoxyribonucleic acids (DNA) and ribo-

nucleic acids (RNA); and proteins, such as ribonucleoproteins and proteins used for immunization, e.g. viral proteins. Examples of DNA for use in the present invention are plasmids and genes, especially those for which gene therapy protocols have been launched such as cystic fibrosis transmembrane regulator (CFTR), adenosine deaminase (ADA), thymidine kinase (tk) and HLA B7; as well as reporter genes such as beta-galactosidase, luciferase, green fluorescence protein (gfp), chloramphenicol transferase and alpha-1 antitrypsin. Other examples of DNA are oligodeoxynucleotides and their analogues used as antisense, aptamer or 'triple-helix' agents. Examples of RNA are ribozymes or oligoribonucleotide antisense molecules.

The nature of the cell which is to be transfected is not narrowly crucial. The cell can be a prokaryotic or eukaryotic cell, a mammalian or a plant cell.

In transfecting a cell using a conjugate of this invention, e.g. a compound of formula I, the cell is contacted with the anionic macromolecule in the presence of an appropriate amount of such compound. The appropriate amount of the conjugate, e.g. a compound of formula I for a given amount of anionic macromolecule depends on their respective charges. The +/- charge ratio between the conjugate and the molecule to be transfected generally varies between 0.1-10, preferably between 0.5-5. The value of "+/- charge ratio" is calculated by dividing the number of positively charged groups on the amino acids in the group R^3 by the number of negative charges of the molecule to be transfected. When the molecule to be transfected is a polynucleotide for example, number of negative charges means the number of negatively charged phosphates in the backbone. The optimal ratio within these ranges depends on the cell to be transfected and is readily ascertained by one of skill in the art to which this invention pertains.

The amount of anionic macromolecules to the number of cells is such that the amount of anionic macromolecule for transfecting 10^4 cells is from 0.1 ng to 10 mg, preferably from 0.2 mg to 2 mg. When the anionic macromolecule is DNA the preferred amount of DNA for transfecting 10^4 cells in vitro is from 0.1 mg to 10 mg. When cells are being transfected in vivo, the preferred amount of DNA is from 0.1 μ g to 1 g.

In a preferred aspect of the invention the transfection is further carried out in the presence of a helper lipid and/or short chain phospholipid, and/or a cationic lipid or any other known transfection competent molecule other than a conjugate of this invention. Any conventional helper lipid can be used. "Helper lipids" are phospholipids which are known to increase delivery of macromolecules to cells when used together with known transfection competent molecules. Examples of helper lipids are phospholipids, such as phosphatidylcholines or phosphatidyl-

ethanolamines or mixtures thereof. Preferred helper lipids are phosphatidylethanolamines, such as dioleoylphosphatidylethanolamine. Any conventional short chain phospholipid can be used. "Short chain phospholipids" are phospholipids containing fatty acid residues, which fatty acid residues contain from 6 to 12 carbon atoms in their backbone. Examples of short chain phospholipids are phosphatidylcholines that carry two C₆₋₁₂ fatty acid residues. Preferred short chain phospholipids are dicapryl- and dicapryloyl phosphatidylcholine.

Examples of transfection competent molecules include cationic lipids as described by J.B. Behr in *Bioconjugate Chem.*, 1994, 5, 382-389 and X. Gao and L. Huang in *Gene Ther.*, 1995, 2, 710-722; polycations as described by A.V. Kabanov and V.A.: Kabanov in *Bioconjugate Chem.*, 1995, 6, 7-20; peptides and polymers and other non-viral gene delivery systems as described by F.D. Ledley in *Human Gene Therapy*, 1995, 6, 1129-1144.

The helper lipid and/or short chain phospholipid and/or a cationic lipid and optionally another additional known transfection competent molecule other than a conjugate of this invention is suitably in the form of a liposome, micelles, organic or aqueous dispersions, or organic or aqueous solutions. The optimal molar ratio between the compound of formula I and the helper lipid is 0.1:50, preferably 1:10. The optimal molar ratio between helper lipid and short-chain phospholipid is 2:20. The optimal molar ratio between the compound of formula I or II and additional transfection competent molecules is 0.1:10.

The present invention also comprises the use of a composition as defined above for transfecting an eukaryotic or prokaryotic cell in vivo or in vitro with an anionic macromolecule, preferably with a polynucleotide.

The invention also comprises the use of compounds of formula (I) as defined above for transfecting a eukaryotic or prokaryotic cell in vivo or in vitro with an anionic macromolecule, preferably with a polynucleotide.

A further embodiment of the present invention is a process for transfecting a cell in vivo or in vitro with an anionic macromolecule, preferably a polynucleotide, comprising contacting a cell in vivo or in vitro with the anionic macromolecule in the presence of a compound of formula (I) or with a composition as defined above.

In addition, the invention is directed to a process for introducing a biologically active anionic molecule into a cell in vivo or in vitro with an anionic macromolecule, comprising contacting a cell in vivo or in vitro with the anionic macromolecule in the presence of a composition or a compound as defined above. This includes also a process for introducing in vivo or in vitro a

biologically active anionic molecule into a cell, comprising contacting in vivo or in vitro a cell with the anionic macromolecule in the presence of a composition or compound as defined above.

Further, the present invention is directed to the use of a compound or composition as defined above for introducing in vivo or in vitro a biologically active molecule into cells.

For transfection, an appropriate amount of a conjugate of this invention, e.g., a compound of formula I is added to the molecule to be transfected (e.g., plasmid DNA), suitably in an aqueous solution. Optionally, a helper lipid and, if desired, a short chain phospholipid and/or a cationic lipid and optionally another additional known transfection competent molecule other than a conjugate of this invention is then added, either in form of liposomes, micelles, or as an organic solution or aqueous dispersion. Alternatively, the molecule to be transfected may be added to a composition comprising a compound in accordance with this invention, a helper lipid, and, if desired, a short chain phospholipid and/or a cationic lipid and optionally another additional known transfection competent molecule other than a conjugate of this invention. The composition may be in solid, liquid, semisolid or aerosol form, suitably in form of liposomes, micelles, or as an organic solution or aqueous dispersion.

For transfecting cells in an animal or human patient the composition can be administered by oral, parenteral (i.v., i.m., s.c., i.d., i.p.) transdermal, pulmonary, nasal, rectal, ocular, ventricular, vascular (catheter) and intratumoral route. Furthermore, the composition can be administered by high velocity impaction administration to the skin surface. The progress of transfection can be measured by appropriate testing protocols which are known to those skilled in the art.

The present invention also refers to a composition comprising at least one compound as defined above and a helper lipid and/or a short chain phospholipid and/or a cationic lipid or optionally another additional transfection competent molecule. In addition, the composition may comprise an anionic macromolecule, preferably a polynucleotide. These compositions may also comprise a polycationic polymer, preferably polyethyleneimine (PEI). The components of these compositions may be in the form of an aqueous or organic solution, an aqueous or organic dispersion, or a liposome or a micelle.

The term "polyethylenimine (PEI)" refers to a synthetic organic, generally branched macromolecule with a high cationic charge/density potential, preferably with a molecular weight of about 25 kDa.

The invention also relates to the use of a compound as above for transfecting a cell with an anionic macromolecule, preferably a polynucleotide.

In accordance with the present invention it has been found that conjugating a lipid to a basic, membrane disturbing peptide having a reversed amide bond results in novel compounds that bind polynucleotides and other anionic macromolecules and can be used for transfection of cells. Thus, the invention is concerned with a process for transfecting a cell with an anionic macromolecule comprising, contacting the cell with the anionic macromolecule in the presence of a compound as described above, so as to transfect the cell with the anionic macromolecule.

The invention also relates to a process for production of large quantities of recombinant proteins in PEI-mediated transfected cells. For example, high-level expression of both G protein coupled receptors and ligand-gated ion channels by the use of Semliki Forest virus (SFV) has been realized. Generally, B_{\max} values of more than 50 pmol receptor per mg protein and receptor densities of more than 3×10^6 receptors per cell have been achieved. To further facilitate large scale protein production optimal conditions for mammalian serum-free suspension cultures have been obtained. Adaptation of BHK, CHO and HEK293 cells to these conditions has allowed efficient infection with SFV vectors to produce large volumes of recombinant protein expressing cell cultures.

Surprisingly, the growth temperature of the cell cultures can have a dramatic effect on the duration and levels of recombinant protein-expression. Expression of recombinant luciferase is increased 5 to 10-fold by lowering the growth temperature of BHK and CHO cells from 37°C to 33°C. The expression time is much longer at 33°C with still high expression 65 hours post-infection.

Moreover, the effect of the temperature on the expression of two 7TM receptors, human neurokinin-1 receptor and rat metabotropic glutamate receptor-2 and the 5-HT₃ ligand-gated ion channel could be shown. A similar effect as observed for luciferase has also been obtained for the receptors. The receptor density is much higher in cells grown at 33°C compared to 37°C. The expression time for receptors is usually restricted to 24 hours in SFV-infected cells, but can be prolonged to 65 hours when cells are cultured at 33°C. This improvement can greatly facilitate production of large quantities of recombinant proteins. Moreover, the utility of the inventive transfection for the rapid expression of heterologous proteins in large scale for adherent cells (CFU) and suspension cells (12 l, 23 l, 60 l fermentors) has been realized. In particular helper lipids in combination with PEI exhibit a high transient gene expression in HEK293 cells and other mammalian cell lines at low DNA concentration. In addition the fre-

quently occurring inhibitory effect of conditioned medium which is a serious problem for scale up expression methods is reduced or even avoided.

The following examples which are not limitative illustrate the invention further.

EXAMPLES

Example 1

a) Preparation of the retro-inverso peptide R³SH

Continuous-flow solid-phase synthesis was performed on a PioneerTM Peptide Synthesis System, starting from Tenta Gel S RAM resin (0.25 mmole/g [Rapp Polymere GmbH, Tübingen, Germany] according to the method described by Atherton and Sheppard, Solid Phase Peptide Synthesis : A Practical Approach (IRL Press Oxford 1989). The base-labile Fmoc group was used for α -amino protection. Side chains were protected with the following protection groups: D-Arg(Pbf), D-Cys(Trt), D-Gln(Trt), D-Lys(Boc), D-Ser(But), D-Thr(But) and D-Trp(Boc). Fmoc-amino acids (2.5 equiv.) were activated with an equivalent amount of TATU (L. A. Carpino J. Am. Chem. Soc. 1993, 115, 4397-4398) and DIPEA. Fmoc deprotection was achieved with 20% piperidine in DMF. D-Gln(Trt)-D-Gln(Trt)-D-Arg(Pbf)-D-Lys(Boc)-D-Arg(Pbf)-D-Lys(Boc)-D-Ile-D-Trp(Boc)-D-Ser(But)-D-Ile-D-Leu-D-Ala-D-Pro-D-Leu-Gly-D-Thr(But)-D-Thr(But)-D-Leu-D-Val-D-Lys(Boc)-D-Leu-D-Val-D-Ala-Gly-D-Ile-D-Cys(Trt)-amide Tenta Gel S-resin (2.0 g) was treated with a mixture (100 ml) of 90% TFA, 2% EDT, 5% H₂O, 3% triisopropylsilane for 6 hours. The reaction mixture was concentrated and poured into diethyl ether and the precipitate was collected by filtration and lyophilized from water. The crude peptide was purified by preparative RP-HPLC. There was obtained homogenous D-Gln-D-Gln-D-Arg-D-Lys-D-Arg-D-Lys-D-Ile-D-Trp-D-Ser-D-Ile-D-Leu-D-Ala-D-Pro-D-Leu-Gly-D-Thr-D-Thr-D-Leu-D-Val-D-Lys-D-Leu-D-Val-D-Ala-Gly-D-Ile-D-Cys-NH₂. 6 TFA.

b) Preparation of a compound of formula IV

The homogenous peptide obtained in paragraph a) above (24.2 mg, 7 mmole) was dissolved in a mixture of 2 ml of 100 mM ammonium acetate buffer, pH 6.5, and 2 ml of acetonitrile. To this solution there was added 7.4 mg of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[3-(2-pyridyldithio)propionate] in 0.5 ml of chloroform. The mixture was stirred at room temperature for 1 hour and the organic solvent was removed by evaporation. The remaining solution was washed 3 times with ethyl acetate and the aqueous phase was lyophilized. There was obtained 28.5 mg of a compound of formula IV wherein R¹ and R² are oleoyl and D-Gln-D-Gln-D-Arg-D-Lys-D-Arg-D-Lys-D-Ile-D-Trp-D-Ser-D-Ile-D-Leu-D-Ala-D-Pro-D-Leu-Gly-D-Thr-D-Thr-D-Leu-D-Val-D-Lys-D-Leu-D-Val-D-Ala-Gly-D-Ile-NH-CH[CONH₂]- (CH₂)₇- is R³. ISP-MS: M = 3722.

Example 2

1 mg of the compound obtained in Example 1 was dissolved in 500 μ l acetonitrile and diluted in 500 μ l sterile pure water (1mg/ml) and stored at 4°C. 15 μ l of a plasmid solution (1mg/ml) and stored at 4°C. 15 μ l of a plasmid solution encoding the soluble human tumor necrosis factor receptor p55 gene was transferred into 1.5 ml medium and mixed. Various amounts of the compound obtained in a) was added, mixed and after 10 min at room temperature the mixture was transferred to 15 ml HEK293(EBNA) cells in suspension.

Table 1 shows the transfection efficiency of the compound as described in Example 1 and the cell viability in serum-free suspension culture.

Table 1

Transient tranfection of HEK293(EBNA) cells					
Compound (mg/ml)	1	2	4	6	10
viability (%)	90 – 95	90 – 95	90 – 95	90 – 95	90 – 95
TNFRp55 (ng/ml)	0.1	0.2	2.5	6.3	83

The data clearly indicate that compound-mediated transfection can be achieved in the absence of detectable cell toxicity effects in serum-free suspension culture of 293 (EBNA) cells.

Example 3

1 mg of the compound obtained in Example 1 was dissolved in 500 μ l acetonitrile and diluted in 500 μ l sterile pure water (1mg/ml) and stored at 4°C. 90 mg polyethyleneimine (PEI), with a molecular weight of 25 kDa, were dissolved in sterile pure water (0.9 mg/ml), neutralized with HCl and sterile filtered and stored at room temperature.

3 μ l of a plasmid solution (1mg/ml) encoding the soluble human tumor necrosis factor receptor p55 gene was diluted in 1.5 ml culture medium and mixed. Various amounts of the compound (1mg/ml) as described in Example 1 were added, mixed, followed by 8.3 μ l PEI

(0.9 mg/ml). After mixing and incubation for 10 min at room temperature the mixture was transferred into 15 ml of HEK293 (EBNA) cells in suspension. Cells which were grown in serum-free suspension culture were transferred into fresh medium before adding the complexes. The released receptor protein was measured 72 hrs post-transfection in the culture medium and expressed as ng receptor per milliliter culture.

Table 2 shows the transfection efficiency of the compound described in Example 1 in combination with PEI by measuring the released receptor protein in serum free suspension culture.

Table 2

Transient transfection of HEK293(EBNA) cells together with PEI					
Compound + polyethyleneimine (mg/ml)	0.02 + 0.5	0.05 + 0.5	0.1 + 0.5	0.15 + 0.5	0 + 0.5
TNFRp55 (ng/ml)	490	800	1120	1100	180

The results clearly indicate the synergistic enhancement of the compound together with PEI. The sequence of adding first the compound followed by PEI to the DNA or vice versa has no detectable influence on the transfection efficiency. No significant changes of the expression levels were observed when the cells were cultured in the presence of 10% serum.

Example 4

1 mg of the compound obtained in Example 1 was dissolved in 500 μ l acetonitrile and diluted in 500 μ l sterile pure water (1mg/ml) and stored at 4°C. 90 mg polyethelenimine, with a molecular weight of 25 kDa, was dissolved in sterile pure water (0.9 mg/ml), neutralized with HCl and sterile filtered and stored at room temperature.

3 μ l of a plasmid solution (1 mg/ml) encoding the luciferase gene was diluted in 1.5 ml culture medium and mixed. 2.25 μ l compound (1mg/ml) as described in Example 1 was added, mixed, and followed by 8.3 μ l PEI (0.9 mg/ml). After mixing and incubation for 10 min at room temperature the mixture was transferred into 15 ml of various cells. Cells which were

grown in serum-free suspension culture were transferred into fresh medium before adding the complexes. The luciferase activity was measured the soluble cell extract after 24 hrs incubation and expressed as relative light unit (RLU) per milligram protein.

Table 3 shows the transfection efficiency of the compound described in Example 1 in combination with PEI by measuring the luciferase activity in serum free suspension culture.

Table 3

Luciferase activity (RLU/ml)			
	Compound	PEI	Compound + PEI
BHK 21 C1	5.2×10^5	2.8×10^7	1.8×10^9
CHO dhfr-	1.4×10^6	3.5×10^7	5.3×10^9
HEK293 (EBNA)	2.2×10^6	3.2×10^9	6.7×10^{10}
HEK293	1.8×10^6	2.9×10^9	6.3×10^{10}
Glioma C6	5.8×10^6	6.5×10^7	3.4×10^9

The results clearly indicate the synergistic enhancement of the compound together with PEI in various cell lines.

Example 5

1 mg of the compound obtained in Example 1 was dissolved in 50 μ l acetonitrile and diluted in 500 μ l sterile pure water (1mg/ml) and stored at 4°C. 90 mg polyethelenimine, with a molecular weight of 25 kDa, was dissolved in sterile pure water (0.9 mg/ml), neutralized with HCl and sterile filtered and stored at room temperature.

3 ml of a plasmid solution (1mg/ml) encoding the green fluorescence protein was diluted in 1.5 ml culture medium and mixed. 2.25 μ l compound (1mg/ml) was added, mixed, and followed by 8.3 μ l PEI (0.9 mg/ml). After mixing and incubation for 10 min at room temperature the mixture was transferred into 15 ml of various cells. Cells which were grown in serum-free suspension culture were transferred into fresh medium before adding the com-

plexes. The transfection efficiency was measured by counting the number of fluorescent cells after 24 hours incubation and expressed as percent transfected cells.

Table 4 shows the transfection efficiency of the compound described in Example 1 in combination with PEI by measuring the green fluorescence within various cell lines in serum-free suspension culture.

Table 4

Amount of fluorescence cells (%) - compound + PEI	
BHK 21 C1	25 (\pm 5)
CHO dhfr ⁻	15 (\pm 5)
HEK293(EBNA)	85 (\pm 5)

Example 6

1 mg of the compound obtained in Example 1 was dissolved in 500 μ l acetonitrile and diluted in 500 μ l sterile pure water (1 mg/ml) and stored at 4°C. 90 mg polyethylenimine, with a molecular weight of 25 kDa, was dissolved in sterile pure water (0.9 mg/ml), neutralized with HCl and sterile filtered and stored at room temperature.

3 ml of a plasmid solution (1 mg/ml) encoding the luciferase gene was diluted in 1.5 ml culture medium and mixed. 2.25 μ l compound (1 mg/ml) as described in Example 1 was added, mixed, and followed by 8.3 μ l PEI (0.9 mg/ml). After mixing and incubation for 10 min at room temperature 0.1 ml of the mixture was transferred into a well containing 1 ml medium of a 12 well plate with various adherent cell lines. Cells which were grown in the presence of 10% serum were incubated during 4 hours post-transfection in serum-free medium. The luciferase activity was measured in the soluble cell extract after 24 hours incubation and expressed as relative light unit (RLU) per milligram protein.

Table 5 shows the transfection efficiency of the compound described in Example 1 in combination with PEI by measuring the luciferase activity in various adherent cell lines.


Table 5

Luciferase activity (RLU/mg Protein)		
	PEI	Compound PEI
HEK293	5.4×10^9	5.3×10^{10}
glioma C6	3.1×10^9	1.9×10^{10}
IMR32	2.2×10^9	7.7×10^9
COS 7	2.9×10^8	1.1×10^{10}
HepG2	$<1 \times 10^8$	8×10^8

The results clearly indicate also the synergistic enhancement of the compound together with PEI in various adherent cell lines.

CLAIMS


1. Conjugates of lipids and basic, membrane disturbing peptides which are compounds of formula



wherein R^1 and R^2 are a hydrocarbyl moiety of a straight-chain or branched-chain, saturated or unsaturated aliphatic carboxylic acid or a phospholipid moiety, R^3 is a basic, membrane disturbing peptide with a reversed amide backbone, Y is C_{2-10} alkylene, X is -C(O)-NH- or -S-S- and salts thereof.

2. The compounds of claim 1 wherein R^1 and R^2 independently are an acyl moiety of a C_{12-20} carboxylic acid.
3. The compounds of claims 1 or 2 wherein R^1 and R^2 are independently selected from lauroyl, palmitoyl, stearoyl and oleoyl.
4. The compounds of claims 1 - 3 wherein X is -S-S-.
5. The compounds of claims 1 - 4 wherein R^3 is Gln-Gln-Arg-Lys-Arg-Lys-Ile-Trp-Ser-Ile-Leu-Ala-Pro-Leu-Gly-Thr-Thr-Leu-Val-Lys-Leu-Val-Ala-Gly-Ile-NH-CH[CONH₂]-CH₂- with a reversed amide backbone or derivatives thereof consisting of at least 50 % D-amino acids.
6. The compounds of claim 1 - 5 wherein R^3 is D-Gln-D-Gln-D-Arg-D-Lys-D-Arg-D-Lys-D-Ile-D-Trp-D-Ser-D-Ile-D-Leu-D-Ala-D-Pro-D-Leu-Gly-D-Thr-D-Thr-D-Leu-D-Val-D-Lys-D-Leu-D-Val-D-Ala-Gly-D-Ile-NH-[CONH₂]-CH-(CH₂)-

7. The compound according to any of claims 1 - 6, which is



8. The peptide Gln-Gln-Arg-Lys-Arg-Lys-Ile-Trp-Ser-Ile-Leu-Ala-Pro-Leu-Gly-Thr-Thr-Leu-Val-Lys-Leu-Val-Ala-Gly-Ile-Cys-NH₂ with a reversed amide backbone and consisting of at least 50 % D-amino acids or derivatives.
9. The peptide of claim 8 which is D-Gln-D-Gln-D-Arg-D-Lys-D-Arg-D-Lys-D-Ile-D-Trp-D-Ser-D-Ile-D-Leu-D-Ala-D-Pro-D-Leu-Gly-D-Thr-D-Thr-D-Leu-D-Val-D-Lys-D-Leu-D-Val-D-Ala-Gly-D-Ile-D-Cys-NH₂ and/or salts and/or solvates thereof.
10. A composition comprising at least one compound as defined in any one of claims 1-7 and a helper lipid and/or a short chain phospholipid and/or a cationic lipid and optionally an additional transfection reagent.
11. The composition of claim 10 comprising in addition an anionic macromolecule, preferably a polynucleotide.
12. The composition of claims 10 or 11 comprising in addition a polycationic polymer, preferably polyethyleneimine.
13. The composition of claims 10 - 12, wherein the components are in the form of an aqueous or organic solution, an aqueous or organic dispersion, or a liposome or a micelle.
14. Use of a composition as defined in any one of claims 10 - 13 for transfecting a eukaryotic or prokaryotic cell in vivo or in vitro with an anionic macromolecule.
15. Use of a composition as defined in any one of claims 10 - 13 for transfecting a eukaryotic or prokaryotic cell in vivo or in vitro with a polynucleotide.

17. Use of a compound as defined in any one of claims 1 - 9 for transfecting a cell in vivo or in vitro with a polynucleotide.
18. A process for transfecting a cell in vivo or in vitro with an anionic macromolecule, comprising contacting a cell in vivo or in vitro with the anionic macromolecule in the presence of a compound as defined in any of claims 1 - 9.
19. A process for transfecting a cell in vivo or in vitro with an anionic macromolecule, comprising contacting a cell in vivo or in vitro with the anionic macromolecule in the presence of a composition as defined in any of claims 10 - 13.
20. Use of a compound as defined in any one of claims 1 - 9 for introducing in vivo or in vitro a biologically active molecule into cells.
21. Use of a composition as defined in any one of claims 10 - 13 for introducing in vivo or in vitro a biologically active molecule into cells.
22. A process for introducing a biologically active anionic molecule into a cell in vivo or in vitro with an anionic macromolecule, comprising contacting a cell in vivo or in vitro with the anionic macromolecule in the presence of a composition as defined in any of claims 10 - 13.
23. A process for introducing in vivo or in vitro a biologically active anionic molecule into a cell, comprising contacting a cell in vivo or in vitro with the anionic macromolecule in the presence of a compound as defined in any of claims 1 - 9.
24. A process for introducing in vivo or in vitro a biologically active anionic molecule into a cell, comprising contacting in vivo or in vitro a cell with the anionic macromolecule in the presence of a composition as defined in any of claims 10 - 13.


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/00, A61K 47/48, 9/127		A3	(11) International Publication Number: WO 99/51629
			(43) International Publication Date: 14 October 1999 (14.10.99)
(21) International Application Number: PCT/EP99/02361 (22) International Filing Date: 7 April 1999 (07.04.99) (30) Priority Data: 98106302.7 7 April 1998 (07.04.98) EP 98124837.0 30 December 1998 (30.12.98) EP (71) Applicant (for all designated States except US): ROCHE DIAGNOSTICS GMBH [DE/DE]; D-68298 Mannheim (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): KITAS, Eric, Argiros [AU/CH]; In der Schappe 5, CH-4144 Arlesheim (CH). SCHLAEGER, Ernst-Jürgen [DE/DE]; Neue Strasse 63, D-79588 Effringen-Kirchen (DE). (74) Common Representative: ROCHE DIAGNOSTICS GMBH; Patent Dept., D-68298 Mannheim (DE).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. (88) Date of publication of the international search report: 23 December 1999 (23.12.99)	

(54) Title: NEW COMPOUNDS FOR DNA-TRANSFECTION



(57) Abstract

The invention relates to conjugates of lipids and basic, modified membrane disturbing peptides, characterized in that the peptides comprises a reversed amide backbone, particularly compounds of formula (I), wherein R¹ and R² are a hydrocarbyl moiety of a straight-chain or branched-chain, saturated or unsaturated aliphatic carboxylic acid or a phospholipid moiety, R³ is a basic, modified membrane disturbing peptide with a reversed amide backbone, Y is C₂₋₁₀ alkylene, X is —C(O)—NH— or —S—S—, and salts thereof.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 99/02361

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K14/00 A61K47/48 A61K9/127

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 784 984 A (HOFFMANN LA ROCHE) 23 July 1997 (1997-07-23) cited in the application	1-4
Y	the whole document	1-24
X	LEGENDRE J Y: "Dioleoylmellitin as a Novel Serum- Insensitive Reagent for Efficient Transfection of Mammalian Cells" BIOCONJUGATE CHEMISTRY, vol. 8, 1 January 1997 (1997-01-01), pages 57-63, XP002088445 ISSN: 1043-1802 cited in the application	1-4
Y	the whole document	1-24



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

24 September 1999

Date of mailing of the international search report

03/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Veronese, A

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 99/02361

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JUVVADI, PADMAJA ET AL: "Synthetic Melittin, Its Enantio, Retro, and Retroenantio Isomers, and Selected Chimeric Analogs: Their Antibacterial, Hemolytic, and Lipid Bilayer Action" J. AM. CHEM. SOC. (1996), 118(38), 8989-8997, 1996, XP002116435	8,9
Y	* See Retroenantiomellitin * figure 1; table 1 ---	1-24
Y	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US SCHLAEGER, E.-J. ET AL: "Synergistic enhancement of transient expression by dioleoyl -melittin (DOM) and polyethylenimine (PEI) in mammalian cells in suspension culture" retrieved from STN Database accession no. 130:61776 XP002116436 abstract & NEW DEV. NEW APPL. ANIM. CELL TECHNOL., PROC. ESACT MEET., 15TH (1998), MEETING DATE 1997, 117-120. EDITOR(S): MERTEN, OTTO-WILHELM;PERRIN, PIERRE; GRIFFITHS, BRYAN. PUBLISHER: KLUWER, DORDRECHT, NETH.	1-24
A	--- DEMPSEY C E: "The Actions of Mellitin on Membranes" BIOCHIMICA ET BIOPHYSICA ACTA. MR. REVIEWS ON BIOMEMBRANES, vol. 1031, 1 January 1990 (1990-01-01), pages 143-161. XP002088446 ISSN: 0304-4157 the whole document	1-24
A	--- LEGENBRE J Y ET AL: "Short-Chain Phospholipids Enhance Amphipatic Peptide-Mediated Gene Transfer" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 217, no. 1, 5 December 1995 (1995-12-05), pages 179-185, XP002088443 ISSN: 0006-291X the whole document -----	1-24

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/ 02361

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 14-24
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 14-24
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.: -
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
See FURTHER INFORMATION SHEET PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claim 1 is formulated ambiguously, the definition of claim R3: " a basic, membrane disturbing peptide with a reversed amide backbone " is obscure, and does not properly define a structural feature characterizing the desired peptide residue.

The use of these property/parameter in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is impossible to compare the property/parameter the applicant has chosen to employ with what is set out in the prior art. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise), namely compounds recited in the examples and claims, closely related compounds and the general idea underlying the application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/02361

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0784984 A	23-07-1997	BR 9700703 A	01-09-1998
		CA 2195169 A	18-07-1997
		JP 9202799 A	05-08-1997
		TR 9700035 A	21-08-1997
<hr/>			